



Clinical trial results: TRaitement Ciblé et PrécOce du Canal Artériel du Prématuré par Ibuprofène Summary

EudraCT number	2011-003063-30
Trial protocol	FR
Global end of trial date	21 June 2019

Results information

Result version number	v1 (current)
This version publication date	27 August 2022
First version publication date	27 August 2022

Trial information

Trial identification

Sponsor protocol code	BRD10/6-O
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01630278
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	CHU NANTES
Sponsor organisation address	5 allée de l'île Gloriette, NANTES, France, 44093
Public contact	Direction de la Recherche, CHU NANTES, 0033 2 53 48 28 84, elodie.faurelpaul@chu-nantes.fr
Scientific contact	Direction de la Recherche, CHU NANTES, 0244768144 2 53 48 28 84, elodie.faurelpaul@chu-nantes.fr

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 May 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	21 June 2019
Global end of trial reached?	Yes
Global end of trial date	21 June 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To examine the effects of early echocardiography-targeted ibuprofen treatment of large patent ductus arteriosus (PDA) on survival without cerebral palsy at 24 months of corrected age

Protection of trial subjects:

Very close follow-up of the patients with biological analysis and clinical exams.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 January 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	France: 337
Worldwide total number of subjects	337
EEA total number of subjects	337

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	337
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Infants were eligible if they delivered between 24 and 27 weeks of gestation.

Pre-assignment period milestones

Number of subjects started	337
Number of subjects completed	337

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	IBUPROFEN
------------------	-----------

Arm description:

A cardiac ultrasound was performed on eligible infants by certified neonatologists 20 at 6-12 hours after birth to establish structural normality, measure the PDA diameter and assess the direction of ductal shunt.

Ibuprofen was administered (intravenous) within 12 hours after birth if large patent ductus arteriosus

Arm type	Experimental
Investigational medicinal product name	IBUPROFEN
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

IBUPROFEN was administered as a short infusion of 20 minutes. The injection volume is brought to 2 ml using either a 9 mg/ml (0.9%) sodium chloride injection or a 50 mg/ml (5%) glucose injection.

Arm title	PLACEBO
------------------	---------

Arm description: -

Arm type	Placebo
Investigational medicinal product name	Sodium chloride
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Placebo was an equivalent volume (2 mL) of 9 mg/mL (0.9%) sodium chloride injection administered intravenously as a short 20-minute infusion

Arm title	SMALL DUCTUS ARTERIOSUS
------------------	-------------------------

Arm description:

No intervention for this group of patient

Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 1	IBUPROFEN	PLACEBO	SMALL DUCTUS ARTERIOSUS
Started	114	114	109
Completed	108	102	101
Not completed	6	12	8
refusal	3	6	2
Lost to follow-up	3	6	6

Baseline characteristics

Reporting groups

Reporting group title	IBUPROFEN
-----------------------	-----------

Reporting group description:

A cardiac ultrasound was performed on eligible infants by certified neonatologists 20 at 6-12 hours after birth to establish structural normality, measure the PDA diameter and assess the direction of ductal shunt.

Ibuprofen was administered (intravenous) within 12 hours after birth if large patent ductus arteriosus

Reporting group title	PLACEBO
-----------------------	---------

Reporting group description: -

Reporting group title	SMALL DUCTUS ARTERIOSUS
-----------------------	-------------------------

Reporting group description:

No intervention for this group of patient

Reporting group values	IBUPROFEN	PLACEBO	SMALL DUCTUS ARTERIOSUS
Number of subjects	114	114	109
Age categorical Units: Subjects			
Preterm newborn infants (gestational age < 28 wks)	114	114	109
Gender categorical Units: Subjects			
Female	61	54	54
Male	53	60	55

Reporting group values	Total		
Number of subjects	337		
Age categorical Units: Subjects			
Preterm newborn infants (gestational age < 28 wks)	337		
Gender categorical Units: Subjects			
Female	169		
Male	168		

End points

End points reporting groups

Reporting group title	IBUPROFEN
Reporting group description:	
A cardiac ultrasound was performed on eligible infants by certified neonatologists 20 at 6-12 hours after birth to establish structural normality, measure the PDA diameter and assess the direction of ductal shunt.	
Ibuprofen was administered (intravenous) within 12 hours after birth if large patent ductus arteriosus	
Reporting group title	PLACEBO
Reporting group description: -	
Reporting group title	SMALL DUCTUS ARTERIOSUS
Reporting group description:	
No intervention for this group of patient	
Subject analysis set title	ITTm
Subject analysis set type	Modified intention-to-treat
Subject analysis set description:	
Our primary analysis used a modified intention-to-treat approach including all infants who were randomized and received the first study dose.	

Primary: 2-year cerebral palsy-free survival rate

End point title	2-year cerebral palsy-free survival rate ^[1]
End point description:	
End point type	Primary
End point timeframe:	
at 2 years	
Notes:	
[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Patients in group 3 were not randomized and were not analyzed as patients in groups 1 and 2.	

End point values	IBUPROFEN	PLACEBO	ITTm	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	108	102	210	
Units: subjects	77	73	150	

Statistical analyses

Statistical analysis title	primary end point
Comparison groups	PLACEBO v IBUPROFEN
Number of subjects included in analysis	210
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.83
Method	Mixed models analysis

Adverse events

Adverse events information

Timeframe for reporting adverse events:
until end of hospitalization

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.0
--------------------	------

Reporting groups

Reporting group title	all patients
-----------------------	--------------

Reporting group description: -

Serious adverse events	all patients		
Total subjects affected by serious adverse events			
subjects affected / exposed	113 / 337 (33.53%)		
number of deaths (all causes)	104		
number of deaths resulting from adverse events			
Vascular disorders			
Shock			
subjects affected / exposed	3 / 337 (0.89%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	1 / 3		
Neonatal hypotension			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemodynamic instability			
subjects affected / exposed	2 / 337 (0.59%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Patent ductus arteriosus repair			
subjects affected / exposed	2 / 337 (0.59%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal			

conditions			
Jaundice neonatal			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
General physical health deterioration			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infusion site extravasation			
subjects affected / exposed	3 / 337 (0.89%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
Multiple organ dysfunction syndrome			
subjects affected / exposed	6 / 337 (1.78%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 6		
Immune system disorders			
Bacillus infection			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Reproductive system and breast disorders			
Ovarian cyst			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Apparent life threatening event			

subjects affected / exposed	2 / 337 (0.59%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Bronchopulmonary dysplasia			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Hypoxia			
subjects affected / exposed	3 / 337 (0.89%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	1 / 3		
Pulmonary arterial hypertension			
subjects affected / exposed	4 / 337 (1.19%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	0 / 1		
Pulmonary haemorrhage			
subjects affected / exposed	10 / 337 (2.97%)		
occurrences causally related to treatment / all	1 / 10		
deaths causally related to treatment / all	0 / 3		
Apnoea			
subjects affected / exposed	2 / 337 (0.59%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Bronchospasm			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neonatal hypoxia			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory acidosis			

subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Investigations			
Oxygen saturation decreased			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Injury, poisoning and procedural complications			
Endotracheal intubation complication			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cardiac disorders			
Atrial thrombosis			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bradycardia			
subjects affected / exposed	2 / 337 (0.59%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cardiac failure			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac tamponade			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardio-respiratory arrest neonatal			
subjects affected / exposed	4 / 337 (1.19%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 3		

Pericardial effusion			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumopericardium			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Nervous system disorders			
Central nervous system haemorrhage			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cerebral haemorrhage			
subjects affected / exposed	3 / 337 (0.89%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	1 / 3		
Intraventricular haemorrhage neonatal			
subjects affected / exposed	23 / 337 (6.82%)		
occurrences causally related to treatment / all	5 / 23		
deaths causally related to treatment / all	2 / 18		
Periventricular leukomalacia			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cerebral infarction			
subjects affected / exposed	2 / 337 (0.59%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 2		
Intracranial pressure increased			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		

Anuria			
subjects affected / exposed	3 / 337 (0.89%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	1 / 2		
Hydrocephalus			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	6 / 337 (1.78%)		
occurrences causally related to treatment / all	1 / 6		
deaths causally related to treatment / all	1 / 1		
Gastrointestinal disorders			
Enterocolitis			
subjects affected / exposed	4 / 337 (1.19%)		
occurrences causally related to treatment / all	2 / 4		
deaths causally related to treatment / all	0 / 1		
Gastrointestinal perforation			
subjects affected / exposed	13 / 337 (3.86%)		
occurrences causally related to treatment / all	10 / 13		
deaths causally related to treatment / all	1 / 2		
Necrotising enterocolitis neonatal			
subjects affected / exposed	7 / 337 (2.08%)		
occurrences causally related to treatment / all	5 / 7		
deaths causally related to treatment / all	1 / 1		
Pneumoperitoneum			
subjects affected / exposed	5 / 337 (1.48%)		
occurrences causally related to treatment / all	2 / 5		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorder			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Gastrointestinal haemorrhage subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Intussusception subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders Hepatic cyst subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Hepatorenal syndrome subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Hyperbilirubinaemia subjects affected / exposed	3 / 337 (0.89%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Jaundice neonatal subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Portal hypertension subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Renal and urinary disorders Oliguria subjects affected / exposed	2 / 337 (0.59%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 1		

Renal failure neonatal			
subjects affected / exposed	9 / 337 (2.67%)		
occurrences causally related to treatment / all	8 / 10		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Bacillus infection			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Escherichia sepsis			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Fungal infection			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Group B streptococcus neonatal sepsis			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Infection			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Meningitis bacterial			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Peritonitis			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	2 / 337 (0.59%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Septic shock			
subjects affected / exposed	8 / 337 (2.37%)		
occurrences causally related to treatment / all	0 / 8		
deaths causally related to treatment / all	0 / 7		
Superinfection			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Systemic candida			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Acidosis			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Dehydration			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Metabolic acidosis			
subjects affected / exposed	4 / 337 (1.19%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	0 / 1		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	all patients		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	82 / 337 (24.33%)		
Surgical and medical procedures			
Abdominal cavity drainage			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences (all)	1		
Colostomy closure			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences (all)	1		
Enterostomy			
subjects affected / exposed	4 / 337 (1.19%)		
occurrences (all)	5		
Enterostomy closure			
subjects affected / exposed	3 / 337 (0.89%)		
occurrences (all)	3		
Gastrointestinal surgery			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences (all)	1		
Ileostomy			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences (all)	1		
Ileostomy closure			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences (all)	1		
Inguinal hernia repair			
subjects affected / exposed	4 / 337 (1.19%)		
occurrences (all)	4		
Intestinal operation			

subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Intestinal resection subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Patent ductus arteriosus repair subjects affected / exposed occurrences (all)	4 / 337 (1.19%) 4		
Skin graft subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Small intestinal resection subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Therapy cessation subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Pregnancy, puerperium and perinatal conditions Jaundice neonatal subjects affected / exposed occurrences (all)	3 / 337 (0.89%) 3		
Respiratory, thoracic and mediastinal disorders Bronchial dysplasia subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Bronchopulmonary dysplasia subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Neonatal respiratory distress syndrome subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Pulmonary arterial hypertension subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Pulmonary haemorrhage			

subjects affected / exposed occurrences (all)	2 / 337 (0.59%) 2		
Pulmonary hypertension subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Congenital, familial and genetic disorders Patent ductus arteriosus subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Beckwith-Wiedemann syndrome subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Cardiac disorders Atrial thrombosis subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Nervous system disorders Intraventricular haemorrhage neonatal subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Periventricular leukomalacia subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	5 / 337 (1.48%) 6		
Thrombocytopenia subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Eye disorders Retinopathy subjects affected / exposed occurrences (all)	2 / 337 (0.59%) 2		
Gastrointestinal disorders			

Abdominal distension subjects affected / exposed occurrences (all)	8 / 337 (2.37%) 8		
Gastrointestinal perforation subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Gastrooesophageal reflux disease subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Ileal perforation subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Inguinal hernia subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Rectal haemorrhage subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Vomiting subjects affected / exposed occurrences (all)	4 / 337 (1.19%) 4		
Hepatobiliary disorders Hyperbilirubinaemia subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Jaundice subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Skin and subcutaneous tissue disorders Skin necrosis subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Renal and urinary disorders Anuria subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Kidney injury molecule-1			

subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Renal failure neonatal subjects affected / exposed occurrences (all)	6 / 337 (1.78%) 6		
Infections and infestations			
Bacillus infection subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Candida infection subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Conjunctivitis subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Cytomegalovirus infection subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Enterococcal infection subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Gardnerella infection subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Gastrointestinal bacterial infection subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Infection subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Meningitis bacterial subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		
Neonatal candida infection subjects affected / exposed occurrences (all)	1 / 337 (0.30%) 1		

Neonatal infection			
subjects affected / exposed	3 / 337 (0.89%)		
occurrences (all)	3		
Nosocomial infection			
subjects affected / exposed	4 / 337 (1.19%)		
occurrences (all)	4		
Respiratory tract infection			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences (all)	1		
Rhinitis			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences (all)	1		
Sepsis			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences (all)	1		
Septic shock			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences (all)	1		
Staphylococcal infection			
subjects affected / exposed	2 / 337 (0.59%)		
occurrences (all)	3		
Metabolism and nutrition disorders			
Acidosis			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences (all)	1		
Dehydration			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences (all)	1		
Glucose tolerance impaired			
subjects affected / exposed	3 / 337 (0.89%)		
occurrences (all)	3		
Hyperkalaemia			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences (all)	1		
Hypernatraemia			

subjects affected / exposed	1 / 337 (0.30%)		
occurrences (all)	1		
Hyponatraemia			
subjects affected / exposed	1 / 337 (0.30%)		
occurrences (all)	1		
Metabolic acidosis			
subjects affected / exposed	3 / 337 (0.89%)		
occurrences (all)	3		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 March 2012	change in consent procedures and extension of follow-up to 24 months
08 January 2013	addition of Cochin Hospital
02 April 2013	Adding of an ancillary study for Nantes's patients
04 March 2014	Prolongation of inclusion period
01 March 2016	Prolongation of inclusion period
04 October 2017	change in investigators and in coordinator
07 February 2018	final analysis carried out in 2 steps

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported